PMID- 23189743
OWN - NLM
STAT- MEDLINE
DCOM- 20130108
LR  - 20181202
IS  - 1001-5302 (Print)
IS  - 1001-5302 (Linking)
VI  - 37
IP  - 15
DP  - 2012 Aug
TI  - [Inhibitory effect of resveratrol on ischemia reperfusion-induced cardiocyte 
      apoptosis and its relationship with PI3K-Akt signaling pathway].
PG  - 2323-6
AB  - OBJECTIVE: To study the effect of resveratol on ischemia reperfusion-induced 
      cardiocyte apoptosis and its relationship with PI3K-Akt signaling pathway. 
      METHOD: Fifty male SD rats were divided randomly into five groups: the control 
      group (SH group), the ischemia reperfusion group (I/R group), the resveratol 
      pretreatment group (Res group), the resveratol pretreatment + wortmannin group 
      (Res +Wom group) and the ischemia reperfusion + wortmannin group (I/R + Wom 
      group). The myocardial ischemia model was established by ligating left coronary 
      artery for 45 min followed by 120 min reperfution, in order to observe the 
      contents of NOS and NO. Cardiac myocyte apoptosis was determined by terminal 
      deoxynueleotidyl transferase-mediated dUTP nick end labeling (TUNEL). Bcl-2 and 
      Bax proteins were detected by immunohistochemistry. The t-Akt and p-Akt signaling 
      protein expressions were determined by Western blotting analysis. RESULT: 
      Compared with the I/R groups and the Res + Wom group, the Res group showed 
      significant increase in the expressions of NOS, NO, Bcl-2 protein and p-Akt and 
      notable decrease in cardiocyte apoptosis and Bax/Bcl-2. The difference of above 
      indicators showed a statistical significance (P<0.05). Furthermore, above changes 
      can be blocked by wortmannin, a specific blocker of PI3K-Akt signaling pathway, 
      indicating a statistical significance in their changes (P<0.05). CONCLUSION: 
      Resveratol can inhibit the ischemia reperfusion-induced cardiocyte apoptosis, in 
      which PI3K-Akt signaling pathway gets involved.
FAU - He, Dongwei
AU  - He D
AD  - Department of Anesthesiology, First Affiliated Hospital of Chongqing Medical 
      University, Chongqing 400016, China. 603155458@qq.com
FAU - Liu, Xinwei
AU  - Liu X
FAU - Pang, Yong
AU  - Pang Y
FAU - Liu, Liu
AU  - Liu L
LA  - chi
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhongguo Zhong Yao Za Zhi
JT  - Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese 
      materia medica
JID - 8913656
RN  - 0 (Stilbenes)
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - Q369O8926L (Resveratrol)
SB  - IM
MH  - Animals
MH  - Apoptosis/*drug effects
MH  - Down-Regulation/drug effects
MH  - Humans
MH  - Male
MH  - Myocardial Reperfusion Injury/*drug therapy/genetics/metabolism/physiopathology
MH  - Myocardium/cytology/metabolism
MH  - Myocytes, Cardiac/*cytology/drug effects/metabolism
MH  - Phosphatidylinositol 3-Kinases/genetics/*metabolism
MH  - Proto-Oncogene Proteins c-akt/genetics/*metabolism
MH  - Rats, Sprague-Dawley
MH  - Resveratrol
MH  - Signal Transduction/*drug effects
MH  - Stilbenes/*administration & dosage
EDAT- 2012/11/30 06:00
MHDA- 2013/01/09 06:00
CRDT- 2012/11/30 06:00
PHST- 2012/11/30 06:00 [entrez]
PHST- 2012/11/30 06:00 [pubmed]
PHST- 2013/01/09 06:00 [medline]
PST - ppublish
SO  - Zhongguo Zhong Yao Za Zhi. 2012 Aug;37(15):2323-6.